Therapeutic application of histone deacetylase inhibitors for central nervous system disorders - PubMed (original) (raw)
Review
doi: 10.1038/nrd2681.
Affiliations
- PMID: 18827828
- DOI: 10.1038/nrd2681
Review
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Aleksey G Kazantsev et al. Nat Rev Drug Discov. 2008 Oct.
Abstract
Histone deacetylases (HDACs)--enzymes that affect the acetylation status of histones and other important cellular proteins--have been recognized as potentially useful therapeutic targets for a broad range of human disorders. Pharmacological manipulations using small-molecule HDAC inhibitors--which may restore transcriptional balance to neurons, modulate cytoskeletal function, affect immune responses and enhance protein degradation pathways--have been beneficial in various experimental models of brain diseases. Although mounting data predict a therapeutic benefit for HDAC-based therapy, drug discovery and development of clinical candidates face significant challenges. Here, we summarize the current state of development of HDAC therapeutics and their application for the treatment of human brain disorders such as Rubinstein-Taybi syndrome, Rett syndrome, Friedreich's ataxia, Huntington's disease and multiple sclerosis.
Similar articles
- Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
Anne-Laurence B, Caroline R, Irina P, Jean-Philippe L. Anne-Laurence B, et al. Subcell Biochem. 2007;41:263-93. Subcell Biochem. 2007. PMID: 17484132 Review. - Creating zinc monkey wrenches in the treatment of epigenetic disorders.
Kalin JH, Butler KV, Kozikowski AP. Kalin JH, et al. Curr Opin Chem Biol. 2009 Jun;13(3):263-71. doi: 10.1016/j.cbpa.2009.05.007. Epub 2009 Jun 21. Curr Opin Chem Biol. 2009. PMID: 19541531 Review. - Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M, Shimazu T, Matsuyama A. Yoshida M, et al. Prog Cell Cycle Res. 2003;5:269-78. Prog Cell Cycle Res. 2003. PMID: 14593721 Review. - Development of histone deacetylase inhibitors for cancer treatment.
Marchion D, Münster P. Marchion D, et al. Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. doi: 10.1586/14737140.7.4.583. Expert Rev Anticancer Ther. 2007. PMID: 17428177 Review. - Recent advances in the discovery of small molecule histone deacetylase inhibitors.
Remiszewski SW. Remiszewski SW. Curr Opin Drug Discov Devel. 2002 Jul;5(4):487-99. Curr Opin Drug Discov Devel. 2002. PMID: 12197307 Review.
Cited by
- Repurposing of known drugs from multiple libraries to identify novel and potential selective inhibitors of HDAC6 via in silico approach and molecular modeling.
Mert NM, Erdogan B, Yelekçi K. Mert NM, et al. Heliyon. 2024 Jul 23;10(15):e35020. doi: 10.1016/j.heliyon.2024.e35020. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39157373 Free PMC article. - Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.
Tenchov R, Sasso JM, Zhou QA. Tenchov R, et al. ACS Chem Neurosci. 2024 Aug 7;15(15):2665-2694. doi: 10.1021/acschemneuro.4c00184. Epub 2024 Jul 12. ACS Chem Neurosci. 2024. PMID: 38996083 Free PMC article. Review. - Inhibition of histone deacetylase promotes a neuroprotective mechanism in an experimental model of Parkinson's disease.
Li H, Shi G, Zha H, Zheng L, Luo Z, Wang Y. Li H, et al. Arch Med Sci. 2021 Mar 5;20(2):664-674. doi: 10.5114/aoms/130287. eCollection 2024. Arch Med Sci. 2021. PMID: 38757033 Free PMC article. - Increasing histone acetylation improves sociability and restores learning and memory in KAT6B-haploinsufficient mice.
Bergamasco MI, Vanyai HK, Garnham AL, Geoghegan ND, Vogel AP, Eccles S, Rogers KL, Smyth GK, Blewitt ME, Hannan AJ, Thomas T, Voss AK. Bergamasco MI, et al. J Clin Invest. 2024 Apr 1;134(7):e167672. doi: 10.1172/JCI167672. J Clin Invest. 2024. PMID: 38557491 Free PMC article. - Plasticity of gene expression in the nervous system by exposure to environmental odorants that inhibit HDACs.
Haga-Yamanaka S, Nunez-Flores R, Scott CA, Perry S, Chen ST, Pontrello C, Nair MG, Ray A. Haga-Yamanaka S, et al. Elife. 2024 Feb 27;12:RP86823. doi: 10.7554/eLife.86823. Elife. 2024. PMID: 38411140 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources